Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Aug 06, 2024 8:45am
164 Views
Post# 36165600

RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work

RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work By ONCY shifting gears into Cantor Fitzgerald, a US based global financial institution with world-class specialized talent with a particular focus on healthcare, biopharmaceuticals, and technology, ONCY throws the doors open to opportunites that the Accelerated Approval pathway can bring for ONCY's pelareorep in combination with paclitaxel for the treatment of HR+/HER2- metastatic Breast Cancer used in 2 different scenarios- (1) either in ADC intolerant mBC patients which was originally planned before ADC therapy, or (2) following ADC therapy (in ADC failure), AND for pelareorep in combination with an immune checkpoint inhibitor for the treatment of pancreatic cancer (PDAC), at a time when the markets are shifting into small cap stocks and Big Pharma is ramping up their M&A activities.
<< Previous
Bullboard Posts
Next >>